This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0885328207078067v1 0885328207078067v2 0885328207078067v3 0885328207078067v4 22/5/449    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Karmaker, S. Articles by Sakurai, H. Search for Related Content PubMed PubMed Citation Articles by Karmaker, S. Articles by Sakurai, H. Social Bookmarking                         What's this?

Antidiabetic Activity of the Orally Effective Vanadyl-Poly (-Glutamic Acid) Complex in Streptozotocin(STZ)-induced Type 1 Diabetic Mice

¹ Department of Chemistry, Colorado State University Fort Collins, CO 80523, USA; Department of Analytical and Bioinorganic Chemistry Kyoto Pharmaceutical University, 5 Nakauchi-cho, Misasagi Yamashina-ku, Kyoto 607-8414, Japan; Department of Chemistry, Jahangirnagar University, Saver, Dhaka 1342, Bangladesh
² Department of Analytical and Bioinorganic Chemistry Kyoto Pharmaceutical University, 5 Nakauchi-cho, Misasagi Yamashina-ku, Kyoto 607-8414, Japan

^* To whom correspondence should be addressed.

	Abstract

Newly synthesized vanadyl-poly(-glutamic acid) complex (VO--PGA) with a VO(O₄) coordination mode was found to have potent antidiabetic activity in streptozotocin (STZ)-induced type 1 diabetic mice (STZ-mice), compared with that of a solution containing only vanadyl sulfate, VOSO₄. This was the first example of orally active vanadyl complex of -PGA for treating STZ-mice. To better define its efficacy, we examined here the effects of VO--PGA treatment in STZ-mice by oral administration at the dose of 10 mg V/kg body mass for a longer period time than our previous study. The improvement in diabetic states in STZ-mice compared with saline-treated nondiabetic normal Std ddY mice. It was found that the elevated blood glucose levels in STZ-mice significantly decreased after 3 days and sustained the normalized blood glucose level around 180-200 mg/dL (10-11.1 mM) for the last 14 days, which is close to the blood glucose levels 100-200 mg/dL (5.6-11.1 mM) in nondiabetic normal Std ddY mice. The improvement in diabetes was strongly corelated by the improvement in oral glucose tolerance ability, glycosylated hemoglobin (HbA_1c) levels and blood pressure, and serum parameters. The present results confirmed that VO--PGA complex is a promising, orally active insulin-mimetic agent to treat type 1 diabetic mice.

Key Words: vanadyl-poly(-glutamic acid) complex, biodegradable polymer, drug delivery system, diabetes, hyperglycemia, STZ-mice

First published on May 10, 2007, doi:10.1177/0885328207078067

Journal of Biomaterials Applications 2008;22:449.

A more recent version of this article appeared on March 1, 2008
This version was published on November 12, 2007


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?